TRADD: A Protein Involved in Immune and Inflammatory Regulation

Target Name: TRADD

NCBI ID: G8717

TRADD

Other Name(s): Hs.89862 | TNFRSF1A associated via death domain, transcript variant 1 | tumor necrosis factor receptor-1-associated protein | Tumor necrosis factor receptor type 1-associated DEATH domain protein | TNFRSF1A-associated via death domain | TRADD_HUMAN | TNFR1-associated death domain protein | Tumor necrosis factor receptor type 1 associated death domain protein | TRADD variant 1 | tumor necrosis factor receptor type 1 associated death domain protein | MGC11078 | Tumor necrosis factor receptor-1-associated protein | TNFR1-associated DEATH domain protein | TNFRSF1A associated via death domain

TRADD: A Protein Involved in Immune and Inflammatory Regulation

TRADD is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of the immune response and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of TRADD is its role in the immune response. TRADD has been shown to play a key role in the regulation of T cell development and function, which are critical for the immune response. Specifically, TRADD has been shown to promote the development and activation of T cells, as well as to regulate the elimination of T cells that are no longer needed.

In addition to its role in the immune system, TRADD is also involved in the regulation of inflammation. TRADD has been shown to play a key role in the regulation of inflammation at the molecular level, by promoting the production of pro-inflammatory cytokines and preventing the production of anti-inflammatory cytokines.

TRADD has also been shown to be involved in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that TRADD is often overexpressed in a variety of cancer types, and that inhibiting TRADD can be a potential therapeutic approach.

In addition to its potential therapeutic applications, TRADD is also an attractive biomarker for a variety of diseases. For example, TRADD has been shown to be a potential biomarker for a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Additionally, TRADD has has been shown to be involved in the regulation of inflammation in a variety of diseases, including cancer and autoimmune disorders, which could make it an attractive biomarker for these diseases as well.

Overall, TRADD is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its functions and to develop effective therapies based on it.

Protein Name: TNFRSF1A Associated Via Death Domain

Functions: Adapter molecule for TNFRSF1A/TNFR1 that specifically associates with the cytoplasmic domain of activated TNFRSF1A/TNFR1 mediating its interaction with FADD (PubMed:7758105, PubMed:8612133, PubMed:23955153). Overexpression of TRADD leads to two major TNF-induced responses, apoptosis and activation of NF-kappa-B (PubMed:7758105, PubMed:8612133). The nuclear form acts as a tumor suppressor by preventing ubiquitination and degradation of isoform p19ARF/ARF of CDKN2A by TRIP12: acts by interacting with TRIP12, leading to disrupt interaction between TRIP12 and isoform p19ARF/ARF of CDKN2A (By similarity)

The "TRADD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRADD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets